Colleoni M, Gaion F, Liessi G, Mastropasqua G, Nelli P, Manente P
Department of Medical Oncology, Ospedale Civile, Castelfranco Veneto, Italy.
Tumori. 1994 Oct 31;80(5):315-26. doi: 10.1177/030089169408000501.
Hepatocellular carcinoma (HCC) remains one of the most common neoplasms worldwide. Curative treatment options include liver transplantation or resection. Unfortunately, most patients still have unresectable or untransplantable HCC due to disease extension or comorbid factors and are therefore candidate only for palliative treatments.
In this review we have analyzed the different medical approaches employed in the treatment of HCC in an attempt to better define their roles.
Palliative medical treatments including systemic chemotherapy, immunotherapy or hormonal manipulation rarely influence survival of the patients. Although a high response rate is often reported with new local therapies such as transcatheter arterial embolization, intraarterial chemotherapy or percutaneous ethanol injection, the real impact of these treatment modalities on patient survival remains to be determined.
One way to improve the diagnosis of HCC patients would be an appropriate approach to evaluate new drugs or treatment modalities. To answer all the open questions, further trials, possibly randomized, should be conducted on a substantial number of patients with homogeneous prognostic factors.
肝细胞癌（HCC）仍是全球最常见的肿瘤之一。根治性治疗方案包括肝移植或肝切除术。不幸的是，由于疾病进展或合并因素，大多数患者的肝癌仍无法切除或无法进行移植，因此仅适合姑息治疗。
在本综述中，我们分析了治疗HCC所采用的不同医学方法，试图更好地明确它们的作用。
姑息性医学治疗，包括全身化疗、免疫治疗或激素治疗，很少影响患者的生存期。尽管经导管动脉栓塞、动脉内化疗或经皮乙醇注射等新的局部治疗方法常报告有较高的缓解率，但这些治疗方式对患者生存期的实际影响仍有待确定。
改善HCC患者诊断的一种方法是采用适当的方法来评估新药或治疗方式。为了回答所有未解决的问题，应该对大量具有同质预后因素的患者进行进一步的试验，可能采用随机试验。
